A study of flurbiprofen spray to reduce throat soreness in patients with upper respiratory tract infection.
A multi-centre, randomised, double-blinded, placebo-controlled, parallel group, multiple dose, study of the effectiveness of 8.75 mg flurbiprofen spray on the severity of throat soreness in patients with sore throat due to upper respiratory tract infection.
Novotech (Australia) Pty Limited
488 participants
May 15, 2012
Interventional
Conditions
Summary
The primary purpose of this study is to assess the effectiveness of a flurbiprofen spray formulation, over a period of three days, in relieving the symptoms of sore throat due to an upper respiratory tract infection. Flurbiprofen lozenges are approved by the Australian government’s health authority, the Therapeutic Goods Administration (TGA) for the relief of pain, swelling and inflammation due to severe sore throat. In this study, a spray formulation of flurbiprofen will be tested to determine if it too is effective in the relief of sore throat.
Eligibility
Inclusion Criteria6
- primary diagnosis: sore throat of onset within the past 4 days due to upper respiratory tract infection (URTI).
- sore throat (greater than or equal to 6) on the Throat Soreness Scale at baseline.
- objective findings confirm the presence of tonsillopharyngitis (greater than or equal to 5 points on the expanded 21-point Tonsillopharyngitis Assessment).
- must have greater than or equal to 50 mm on the Difficulty Swallowing Scale at Baseline
- must have greater than or equal to 33 mm on the Swollen Throat Scale at Baseline.
- written informed consent.
Exclusion Criteria30
- People with any of the following are unable to participate in the study:
- previous history of allergy or known intolerance to the study drug or the following formulation constituents: xylitol, mannitol, carbomer 974P, sodium bicarbonate, mint, peppermint, aspartame, citric acid, silicon dioxide; or paracetamol or any excipients in the Paracetamol formulation; or aspirin or NSAID’s
- sore throat present for more than 4 days.
- evidence of mouth breathing or severe coughing.
- gastric sensitivity to NSAID’s or a history of gastrointestinal bleeding or perforation, severe colitis, haemorrhagic or haematopoietic disorders related to previous NSAID therapy
- active or history of recurrent peptic ulcer/haemorrhage or intestinal ulceration.
- existing stomach ulcers or a history of stomach ulcers.
- history of bronchospasm, rhinitis or urticaria associated with aspirin or NSAID’s.
- uncontrolled asthma and those who have had an asthma attack in the last 8 weeks.
- uncontrolled hypertension or severe heart failure.
- systemic lupus erythmatosus or mixed connective tissue disease.
- potential for abnormal bleeding.
- any disease that can compromise breathing e.g. bronchopneumonia.
- those who have:
- taken any medicated confectionary, throat pastille, spray, or any product with demulcent properties such as boiled sweets in the previous 2 hours.
- used any sore throat medication containing a local anaesthetic within the previous 4 hours.
- used any analgesic, antipyretic or cold medication (e.g. decongestant, antihistamine, antitussive or throat lozenge) within the previous 8 hours.
- used a longer acting or slow release analgesic during the previous 24 hours e.g. Piroxicam and Naproxen.
- taken antibiotics during the previous 14 days
- taken carbamezepine, phenobarbitone, phenytoin, primidone, rifampicin, St Johns Wort or other drugs that induce liver enzymes in the 14 days before enrolment into the study (i.e. before first dosing day).
- those taking:
- NSAIDs including cyclooxygenase-2 selective inhibitors
- warfarin and other coumarins
- any painful condition that may distract attention from sore throat pain e.g. mouth ulcers etc.
- history of severe renal or hepatic impairment; or alcohol abuse or state that they regularly consume alcohol in excess of the recommended amounts (excessive alcohol >21 units per week for females and >28 units per week for males.).
- are glutathione-deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
- any painful condition that requires analgesic usage.
- unable to refrain from smoking during their stay in the 20. women of childbearing potential, who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral or injectable contraceptive, an approved hormonal implant or topical patch or an intrauterine device).
- previously randomised into the study; or have participated in a clinical trial in the previous 30 days.
- unable in the opinion of the investigator to comply fully with the study requirements, e.g. such as those who cannot comprehend or correctly use thepain rating scales.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervention: Flurbiprofen spray formulation, containing flurbiprofen 8.75 mg /540 microlitres (3 sprays aimed towards the back of the mouth equal 1 dose). Eligible participants will receive their first dose of randomised treatment in the clinic. They should not take their second dose until 6 hours later. Subsequent doses should be taken every 3-6 hours; up to a maximum of 5 doses per day. Participants will continue to take trial medication until their sore throat resolves or the end of Day 3 of study treatment, whichever occurs first. Rescue Medication: paracetamol 500 mg tablets. Only if required, one to two tablets orally every four hours (to a maximum of eight tablets in 24 hours). Not to be take for more than three days.
Locations(2)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000457842